

FLORIDA MEDICAL ASSOCIATION

DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS FOR PLANNERS, REVIEWERS, FACULTY, AND AUTHORS

All persons who influence the content of CME activities are required to disclose relevant financial relationships with any ineligible companies. This includes planners, activity directors, presenters, authors, and administrative staff who participate in the design and development of content, as well as CME Committee members and reviewers who vet and approve proposed content. The intent of this form is to inform planners/presenters/reviewers of their obligations and to support the FMA in mitigating potential conflicts of interest, thus assuring balance, independence, objectivity and scientific rigor in all accredited content.

Name:		_	vity Director	Presenter/Author	Reviewer
Title of Activity/Topic:					
Activity Date:		Date this form o	completed:		
☐ Directly Provided Activity ☐	Jointly Provided act	tivity – Organization ho	sting the meeti	ng:	
☐ Check here if completing this	form as a CME Com	mittee member or revie	ewer for a caler	ndar year	
Check the appropriate box below Do you (now or within the past * You must disclose all financial relations	st 24 months) have	a financial relationsh	ip with an ine	ligible company?*	_
FINANCIAL RELATIONSHIP	COMMERCIAL INTER	REST	CHECK THE B	OX IF THE RELATIONSH	P HAS ENDED
Employee					
Grant/Research Support					
Consultant/Advisor/Contractor					
Speaker's Bureau					
Stock Shareholder					
Other Financial/Material Support					
By checking this box and sub	mitting this form, you	agree to comply with	the following co	onditions:	

- 1. If I have indicated a financial relationship or interest, I understand that this information will be reviewed to determine whether this relationship precludes my participation, and I may be asked to provide additional information.
- I understand that it is necessary to update disclosure information should my status change.
- 3. I understand that failure or refusal to disclose, false disclose, or inability to mitigate conflicts of interest will disqualify me from participating in this activity.
- 4. I will support my presentation and clinical recommendations with the best available evidence from current medical literature. All scientific research referred to, reported or used in support or justification of patient care recommendations will conform to the generally accepted standards of experimental design, data collection and analysis.
- 5. I will give a balanced view of ALL therapeutic options and use generic names when discussing pharmaceutical products.
- 6. I will disclose unlabeled use of a product or an investigational use of a product not yet approved by the FDA.
- 7. I have not nor will I accept any honoraria/additional payments beyond that which has been agreed upon with the FMA.

GLOSSARY OF TERMS:

- **INELIGIBLE COMPANY** The ACCME defines a "ineligible company" as any entity whose primary business is producing, marketing, re-selling, or distributing health care goods or services used by or patients. Entities that provide clinical service directly to patients are exempted.
- FINANCIAL RELATIONSHIPS are defined as those in which a person benefits by receiving a tangible financial benefit (e.g., salary, royalty, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds). Financial benefits are usually associated with roles such as employment, management positions, independent contractor, consulting, speaking and teaching, membership on advisory committees or review panels, board memberships, and other activities from which remuneration is received, or expected.
- The ACCME defines "RELEVANT' financial relationships" as financial relationships in <u>any</u> amount occurring <u>within the past 24 months</u> that may create a CONFLICT OF INTEREST which potentially results when an individual has an opportunity to influence CME content that relates to the products or services of the ineligible company with which he/she has a financial relationship. It is the obligation of the CME provider to determine relevance.